Discover groundbreaking advancements in the treatment of brain metastases in advanced HER2+ breast cancer. New data showcase the transformative potential of novel HER2-targeted therapies, offering improved outcomes for patients. As the treatment landscape rapidly evolves, mastering the intricacies of these innovative agents is essential for crafting patient-centered care plans. Elevate your expertise and stay at the forefront of detection and management of brain metastases in HER2+ breast cancer with this cutting-edge program. In the first Clinical Case Challenge in this series, test your skills in evaluating current evidence and applying individualized strategies for managing brain metastases in advanced HER2+ breast cancer through shared decision-making. See how your responses compare to your peers and receive real-time evidence-based expert commentary from a leading breast oncologist.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/management-her2-plus-mbc-brain-metastases
- Start Date: 2024-12-30 06:00:00
- End Date: 2024-12-30 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 31000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 4714.29 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all